The outcome of phtients with multiple myeloma (MM) is unsatisfactory, with a median survival of less than 3 years.1,2 The prospects for survival at 10 years are poor with conventional chemotherapy.3,4 The limited efficacy of conventional treatment prompted the introduction of high-dose therapy (HDT) followed by stem cell support in an attempt to achieve a greater tumor reduction with longer disease-free and overall survival (OS). Not all patients in whom HDT is feasible obtain a significant benefit from the procedure.
|Original language||English (US)|
|Number of pages||9|
|State||Published - Nov 15 2003|
ASJC Scopus subject areas
- Cell Biology